We are live on ! Find out more
TSHA icon

Taysha Gene Therapies
TSHA

109 hedge funds and large institutions have $402M invested in Taysha Gene Therapies in 2024 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 29 increasing their positions, 27 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

157% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 14

74% more capital invested

Capital invested by funds: $231M → $402M (+$171M)

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

25% more funds holding

Funds holding: 87 → 109 (+22)

5.23% more ownership

Funds ownership: 69.72% → 74.96% (+5.2%)

7% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 27

2% less call options, than puts

Call options by funds: $453K | Put options by funds: $462K

Holders
109
Holders Change
+22
Holders Change %
+25.29%
% of All Funds
1.57%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
36
Increased
29
Reduced
27
Closed
14
Calls
$453K
Puts
$462K
Net Calls
-$9K
Net Calls Change
-$207K

Top Buyers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
+$29.8M
2
Morgan Stanley
Morgan Stanley
New York
+$9.87M
3
OCA
Octagon Capital Advisors
New York
+$6.31M
4
EAM
Eagle Asset Management
Florida
+$3.73M
5
RI
RTW Investments
New York
+$3.54M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$15.8M
2
TCM
TCG Crossover Management
California
-$5.16M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.85M
4
Citadel Advisors
Citadel Advisors
Florida
-$4.79M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$3.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$2.93M +$71.6K +34,370 +3%
GTC
27
Ghost Tree Capital
New York
$2.73M -$2.4M -1,150,000 -55%
SCM
28
Soleus Capital Management
Connecticut
$2.65M +$1.93M +925,000 New
PAI
29
Palo Alto Investors
California
$2.33M +$586K +281,407 +53%
SCV
30
Sands Capital Ventures
Virginia
$2.08M – – –
QPW
31
Quantum Private Wealth
Florida
$2M +$123K +59,000 +9%
AI
32
Alphabet Inc
California
$1.84M – – –
SSA
33
Schonfeld Strategic Advisors
New York
$1.59M -$1.18M -566,780 -51%
HF
34
HRT Financial
New York
$1.19M +$865K +414,980 New
State Street
35
State Street
Massachusetts
$974K +$409K +196,300 +137%
Renaissance Technologies
36
Renaissance Technologies
New York
$943K -$1.6M -768,900 -70%
Kovitz Investment Group Partners
37
Kovitz Investment Group Partners
Illinois
$797K – – –
Citigroup
38
Citigroup
New York
$732K -$116K -55,760 -18%
MTIM
39
Marathon Trading Investment Management
Pennsylvania
$643K +$467K +223,900 New
Adage Capital Partners
40
Adage Capital Partners
Massachusetts
$631K -$417K -200,000 -48%
Squarepoint
41
Squarepoint
New York
$614K +$314K +150,469 +237%
Northern Trust
42
Northern Trust
Illinois
$607K -$4.85K -2,326 -1%
UBS Group
43
UBS Group
Switzerland
$543K +$386K +185,341 +4,701%
Balyasny Asset Management
44
Balyasny Asset Management
Illinois
$542K +$393K +188,698 New
PAS
45
Point72 Asia (Singapore)
Singapore
$520K +$378K +181,306 New
TD Asset Management
46
TD Asset Management
Ontario, Canada
$504K – – –
BHCM
47
Brevan Howard Capital Management
Jersey
$496K +$360K +172,769 New
LCM
48
Laurion Capital Management
New York
$471K +$342K +164,258 New
CSS
49
Cubist Systematic Strategies
Connecticut
$462K +$235K +112,666 +233%
DC
50
Diametric Capital
Massachusetts
$440K +$176K +84,607 +123%
1
2
3 4 5

TSHA Hedge Fund Activity: Q1 2024 in Review

109 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Taysha Gene Therapies (TSHA) for Q1 2024, worth a combined $402M — up 74% from $231M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new TSHA positions and 14 closed out — a net gain of 22 holders — while 29 added to existing stakes and 27 trimmed.

The largest buyer was Avoro Capital Advisors, adding an estimated $29.8M. The largest seller was RA Capital Management, cutting an estimated $15.8M.

  • 109 institutional investors held Taysha Gene Therapies (TSHA) as of Q1 2024, up from 87 in Q4 2023.
  • Funds reported $402M of Taysha Gene Therapies stock for Q1 2024, up 74% quarter-over-quarter.
  • 36 funds opened new Taysha Gene Therapies positions in Q1 2024 and 14 closed out, a net change of +22 holders.
  • The largest Taysha Gene Therapies buyer in Q1 2024 was Avoro Capital Advisors, an estimated $29.8M added.
  • The largest Taysha Gene Therapies seller in Q1 2024 was RA Capital Management, an estimated $15.8M sold.

Based on aggregated 13F filings for Q1 2024.